Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Fully Funded Biotech Plans Proof-Of-Concept In Man by End-2025

 
• By Sten Stovall
  
Emerging Company Profile: ADCendo
uPARAP is overexpressed on the cell surface of several cancers • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

More from Start-Ups & SMEs